Protagonist Therapeutics Inc (PTGX)
Working capital turnover
Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 315,090 | 60,137 | 123 | 123 | 982 | 26,704 | 35,221 | 45,507 | 46,913 | 27,380 | 24,330 | 27,139 | 31,091 | 28,549 | 25,678 | 12,604 | 6,408 | 4,321 | 3,955 | 10,051 |
Total current assets | US$ in thousands | 627,553 | 355,577 | 324,881 | 316,941 | 235,736 | 243,077 | 276,617 | 304,302 | 341,522 | 340,736 | 327,687 | 371,818 | 285,508 | 315,606 | 204,151 | 217,466 | 125,986 | 145,311 | 144,023 | 137,320 |
Total current liabilities | US$ in thousands | 39,910 | 21,274 | 27,867 | 26,398 | 23,229 | 31,179 | 36,754 | 40,088 | 43,456 | 44,016 | 39,156 | 42,973 | 34,515 | 40,241 | 38,563 | 35,360 | 36,372 | 35,406 | 30,776 | 33,323 |
Working capital turnover | 0.54 | 0.18 | 0.00 | 0.00 | 0.00 | 0.13 | 0.15 | 0.17 | 0.16 | 0.09 | 0.08 | 0.08 | 0.12 | 0.10 | 0.16 | 0.07 | 0.07 | 0.04 | 0.03 | 0.10 |
March 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $315,090K ÷ ($627,553K – $39,910K)
= 0.54
The working capital turnover ratio measures how efficiently a company utilizes its working capital to generate sales revenue. A high working capital turnover ratio indicates that the company is effectively managing its working capital to support sales growth.
Protagonist Therapeutics Inc's working capital turnover has shown fluctuations over the periods analyzed. In the latest quarter, ending March 31, 2024, the working capital turnover ratio was 0.54, indicating that the company generated $0.54 in revenue for every dollar of working capital invested. This represents a significant improvement compared to the previous quarter, where the ratio was 0.18.
Looking at the trend over multiple periods, the working capital turnover ratio has shown variability, with some quarters reporting low or even zero turnover. This suggests that Protagonist Therapeutics may have faced challenges in efficiently utilizing its working capital to generate sales revenue during certain periods.
Overall, Protagonist Therapeutics Inc's working capital turnover ratio has displayed improvement in the latest quarter, indicating better efficiency in utilizing its working capital to support sales. Monitoring this ratio over time can provide insights into the company's working capital management effectiveness and operational performance.
Peer comparison
Mar 31, 2024